UN
RELENTING

Our serial innovation approach to CAR T cell development means that each new generation builds on previous discoveries, resulting in iterative advancements in safety and efficacy.

Our current pipeline

A diversified portfolio of validated and novel targets in cross-clinical development addressing the needs of a range of hematologic and solid tumors.

The table illustrates our research and development programs and opportunities as of 4Q2022. Full pipeline not shown.